PT  - JOURNAL ARTICLE
AU  - Gianluca Rinaldi
AU  - Matteo Paradisi
TI  - An empirical estimate of the infection fatality rate of COVID-19 from the first Italian outbreak
AID  - 10.1101/2020.04.18.20070912
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.18.20070912
4099  - http://medrxiv.org/content/early/2020/04/23/2020.04.18.20070912.short
4100  - http://medrxiv.org/content/early/2020/04/23/2020.04.18.20070912.full
AB  - Background The coronavirus 2019 (COVID-19) pandemic has been spreading globally for months, yet the infection fatality ratio of the disease is still uncertain. This is partly because of inconsistencies in testing and death reporting standards across countries. Our purpose is to provide accurate estimates which do not rely on testing and death count data directly but only use population level statistics.Methods We collected demographic and death records data from the Italian Institute of Statistics. We focus on the area in Italy that experienced the initial outbreak of COVID-19 and estimated a Bayesian model fitting age-stratified mortality data from 2020 and previous years. We also assessed the sensitivity of our estimates to alternative assumptions on the proportion of population infected.Findings We estimate an overall infection fatality rate of 1·29% (95% credible interval [CrI] 0·89 − 2·01), as well as large differences by age, with a low infection fatality rate of 0·05% for under 60 year old (CrI 0 − 0·19) and a substantially higher 4·25% (CrI 3·01 − 6·39) for people above 60 years of age. In our sensitivity analysis, we found that even under extreme assumptions, our method delivered useful information. For instance, even if only 10% of the population were infected, the infection fatality rate would not rise above 0 2% for people under 60.Interpretation Our empirical estimates based on population level data show a sharp difference in fatality rates between young and old people and firmly rule out overall fatality ratios below 0·5% in populations with more than 30% over 60 years old.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all data in the study and had final responsibility for the decision to submit for publication.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available and can be found at the cited sources. https://github.com/moritzplatz/covid_IFR_Lombardy